Metastatic Non-Seminomatous Testis Tumors: Morbidity of Treatment
- 1 October 1980
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 124 (4) , 479-481
- https://doi.org/10.1016/s0022-5347(17)55502-0
Abstract
Patients (28) with metastatic non-seminomatous testis tumors were treated with a regimen of combined retroperitoneal lymphadenectomy and multiple drug chemotherapy [vinblastine sulfate, bleomycin and actinomycin D]. The morbidity of this plan of management was outlined with a followup of 3 to 8 yr. Survival for all patients with stage B disease is 100% and with stage C disease is 58% (8 of 14 patients).This publication has 6 references indexed in Scilit:
- Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in manCancer, 1978
- Carcinoma of the testisCancer, 1977
- Improved Chemotherapy in Disseminated Testicular CancerJournal of Urology, 1977
- Serum Alpha Fetoprotein and Human Chorionic Gonadotropin in the Diagnosis and Management of Nonseminomatous Germ-Cell Testicular CancerNew England Journal of Medicine, 1976
- Non-Seminomatous Testis Tumors: a Plan of Management Based on 96 Patients to Improve Survival in All Stages by Combined Therapeutic ModalitiesJournal of Urology, 1976
- Effects of Combined Drug Therapy on Metastatic Cancer of the TestisJAMA, 1960